SCHEMBL2547176

SCHEMBL2547176

N#COC(=O)C=Cc1ccc(O)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 6/20 0.61
▸ CA7 P43166 6/20 0.61
▸ CA9 Q16790 6/20 0.61
▸ CA14 Q9ULX7 6/20 0.61
▸ CA1 P00915 5/20 0.61
▸ CA2 P00918 4/20 0.61
▸ TYR P14679 3/20 0.61
▸ AKR1B10 O60218 6/20 0.56
▸ AKR1B1 P15121 6/20 0.56
▸ F3 P13726 2/20 0.55
▸ CYP2D6 P10635 1/20 0.55
▸ CYP2C9 P11712 1/20 0.55
▸ HSD11B1 P28845 1/20 0.55
▸ CA4 P22748 3/20 0.53
▸ CA6 P23280 3/20 0.53
▸ CA5A P35218 3/20 0.53
▸ CA5B Q9Y2D0 3/20 0.53
▸ PKM P14618 2/20 0.53
▸ ESR1 P03372 1/20 0.53
▸ CA3 P07451 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1299521 1.00 CA12 (0.61) CA12CA7CA9CA14CA1
SCHEMBL8359765 0.84 MAPT (0.53) CA12CA7CA9CA14AKR1B10
SCHEMBL8359766 0.84 MAPT (0.53) CA12CA7CA9CA14AKR1B10
SCHEMBL10719558 0.81 JUN (0.53) CA12CA7CA9CA14CA1
SCHEMBL22026690 0.81 F3 (0.62) F3MAOBP4HBGSK3BBACE1
SCHEMBL30665840 0.81 AKR1B10 (0.52) AKR1B10AKR1B1MAOBP4HBMMP2
SCHEMBL8745007 0.81 APP (0.64) CA12CA7CA9CA14CA1
SCHEMBL1478808 0.81 F3 (0.62) F3MAOBP4HBGSK3BBACE1
SCHEMBL10891552 0.79 CA12 (0.71) CA12CA7CA9CA14CA1
SCHEMBL3314742 0.79 CA12 (0.71) CA12CA7CA9CA14CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011123788-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER DUKE UNIVERSITY (US) 2011-10-06 — — WO claimed
US-12528903-B2 Block copolymer and micelle compositions and methods of use thereof THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2026-01-20 — — US disclosed
CN-118583946-A Analysis method for rapidly screening excessive phenylalanine in blood spot sample 南京中医药大学 2024-09-03 — — CN disclosed
CN-117192671-A Polarizing plate with phase difference layer 日东电工株式会社 2023-12-08 — — CN disclosed
CN-117192672-A Resin film, method for producing resin film, and method for producing phase difference film 日东电工株式会社 2023-12-08 — — CN disclosed
CN-112851929-B Ce6 derivative, nano preparation thereof, and preparation method and application thereof 山东大学 2022-02-11 — — CN disclosed
EP-2855532-A1 IDENTIFICATION AND FUNCTIONAL EXPRESSION OF THE MITOCHONDRIAL PYRUVATE CARRIER, MPC1 University of Geneva (CH) 2015-04-08 — — EP disclosed
WO-2013175015-A1 IDENTIFICATION AND FUNCTIONAL EXPRESSION OF THE MITOCHONDRIAL PYRUVATE CARRIER, MPC1 UNIVERSITY OF GENEVA (CH) 2013-11-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12528903-B2 Block copolymer and micelle compositions and methods of use thereof PHOSPHO1, SGMS1, PCTP CA12 932/4885CA7 2470/4885CA9 2379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback